$INM
InMed Pharmaceuticals Inc. Stock $inm

$inm Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000121390024042467 Filed on May 14, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$1.283M	$1.173M	$1.034M
YoY Change	-44.46%	13.41%	233.97%
Cost Of Revenue	$817.0K	$883.1K	$841.4K
YoY Change	10.41%	4.96%	560.92%
Gross Profit	$466.1K	$289.5K	$192.5K
YoY Change	-70.31%	50.36%	5.61%
Gross Profit Margin	36.32%	24.69%	18.62%
Selling, General & Admin	$1.214M	$1.374M	$1.413M
YoY Change	-13.91%	-2.73%	-26.23%
% of Gross Profit	260.46%	474.71%	733.84%
Research & Development	$1.206M	$656.8K	$878.3K
YoY Change	94.58%	-25.22%	-49.91%
% of Gross Profit	258.84%	226.89%	456.24%
Depreciation & Amortization	$54.77K	$14.22K	$50.69K
YoY Change	9.54%	-71.95%	-4.97%
% of Gross Profit	11.75%	4.91%	26.33%
Operating Expenses	$2.475M	$2.134M	$2.342M
YoY Change	18.42%	-8.88%	-37.08%
Operating Profit	-$2.009M	-$1.844M	-$1.998M
YoY Change	286.35%	-7.69%	-43.55%
Interest Expense	$78.44K	$73.30K	$152.8K
YoY Change	-56.42%	-52.02%	138.84%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$1.931M	-$1.723M	-$1.996M
YoY Change	467.81%	-13.7%	-42.56%
Income Tax	$7.100K	$0.00	$1.500K
% Of Pretax Income
Net Earnings	-$1.938M	-$1.723M	-$1.998M
YoY Change	469.9%	-13.77%	-42.52%
Net Earnings / Revenue	-151.02%	-146.93%	-193.24%
Basic Earnings Per Share		-$0.18	-$0.60
Diluted Earnings Per Share	-$0.20	-$0.18	-$0.60
COMMON SHARES
Basic Shares Outstanding	8.358M shares	6.057M shares	3.328M shares
Diluted Shares Outstanding		9.613M shares	3.328M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$6.615M	$7.644M	$9.647M
YoY Change	-26.18%	-20.77%	62.29%
Cash & Equivalents	$6.572M	$7.601M	$9.604M
Short-Term Investments	$43.06K	$43.09K	$43.06K
Other Short-Term Assets	$477.8K	$1.019M	$695.2K
YoY Change	-4.45%	46.53%	-46.99%
Inventory	$1.244M	$1.194M	$1.330M
Prepaid Expenses
Receivables	$352.8K	$207.7K	$170.3K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$8.690M	$10.06M	$11.84M
YoY Change	-23.32%	-15.02%	35.39%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.250M	$1.371M	$753.2K
YoY Change	72.79%	82.01%	-24.89%
Goodwill
YoY Change
Intangibles	$1.783M	$1.824M	$1.987M
YoY Change	-8.38%	-8.21%
Long-Term Investments
YoY Change
Other Assets	$100.0K	$100.0K	$147.5K
YoY Change	-4.68%	-32.2%	35.77%
Total Long-Term Assets	$3.133M	$3.295M	$2.888M
YoY Change	12.92%	14.1%	-57.15%
TOTAL ASSETS
Total Short-Term Assets	$8.690M	$10.06M	$11.84M
Total Long-Term Assets	$3.133M	$3.295M	$2.888M
Total Assets	$11.82M	$13.36M	$14.73M
YoY Change	-16.19%	-9.31%	-4.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$41.00K	$402.6K	$737.5K
YoY Change	-92.41%	-45.4%	-56.0%
Accrued Expenses	$256.5K	$167.5K	$1.516M
YoY Change	-82.19%	-88.95%	-4.69%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.972M	$1.529M	$2.270M
YoY Change	-1.44%	-32.64%	-44.72%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$644.9K	$725.2K	$72.79K
YoY Change	3124.35%	896.35%	-85.25%
Total Long-Term Liabilities	$644.9K	$725.2K	$72.79K
YoY Change	3124.35%	896.35%	-85.25%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.972M	$1.529M	$2.270M
Total Long-Term Liabilities	$644.9K	$725.2K	$72.79K
Total Liabilities	$2.617M	$2.254M	$2.342M
YoY Change	29.76%	-3.77%	-49.07%
SHAREHOLDERS EQUITY
Retained Earnings	-$109.1M	-$107.1M	-$101.1M
YoY Change	7.59%	5.97%
Common Stock	$118.2M	$118.1M	$77.62M
YoY Change	52.22%	52.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.206M	$11.10M	$12.39M
YoY Change
Total Liabilities & Shareholders Equity	$11.82M	$13.36M	$14.73M
YoY Change	-16.19%	-9.31%	-4.88%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$1.938M	-$1.723M	-$1.998M
YoY Change	469.9%	-13.77%	-42.52%
Depreciation, Depletion And Amortization	$54.77K	$14.22K	$50.69K
YoY Change	9.54%	-71.95%	-4.97%
Cash From Operating Activities	-$1.029M	-$5.957M	-$1.657M
YoY Change	58.33%	259.56%	-69.03%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$9.290K	$0.00
YoY Change	-100.0%		-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	-$128.2K
YoY Change	-100.0%	-100.0%
Cash From Investing Activities	$0.00	-$9.290K	-$128.2K
YoY Change	-100.0%	-92.75%	3511.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	180.0	4.654M	-63.70K
YoY Change		-7406.19%	117.33%
NET CHANGE
Cash From Operating Activities	-1.029M	-5.957M	-1.657M
Cash From Investing Activities	0.000	-9.290K	-128.2K
Cash From Financing Activities	180.0	4.654M	-63.70K
Net Change In Cash	-1.029M	-1.312M	-1.849M
YoY Change	51.32%	-29.03%	-65.65%
FREE CASH FLOW
Cash From Operating Activities	-$1.029M	-$5.957M	-$1.657M
Capital Expenditures	$0.00	$9.290K	$0.00
Free Cash Flow	-$1.029M	-$5.966M	-$1.657M
YoY Change	27.06%	260.13%	-69.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Common Stock No Par Value CommonStockNoParValue
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.53
CY2023Q2	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2024Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet		usd
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.18
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.82
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	3328191	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6961938	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2156283	shares
CY2024Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent		usd
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	A1
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1428279
	dei	Entity Address Country EntityAddressCountry	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	V6C 1B4
	dei	Security12b Title Security12bTitle	Common Shares, no par value
	dei	Trading Symbol TradingSymbol	INM
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.60
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-39685
	dei	Entity Registrant Name EntityRegistrantName	INMED PHARMACEUTICALS INC.
	dei	Entity Address Address Line1 EntityAddressAddressLine1	Suite 310 - 815 W. Hastings Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Vancouver
	dei	Entity Address City Or Town EntityAddressCityOrTown	B.C
	dei	City Area Code CityAreaCode	(604)
	dei	Local Phone Number LocalPhoneNumber	669-7207
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8357956	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7600598	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8912517	usd
CY2024Q1	us-gaap	Short Term Investments ShortTermInvestments	43085	usd
CY2023Q2	us-gaap	Short Term Investments ShortTermInvestments	44422	usd
CY2024Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	66775	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	66775	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	207681	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	260399	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	1193952	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	1616356	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1018686	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	498033	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	10064002	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	11331727	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1370969	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	723426	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1823745	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1946279	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	100000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	104908	usd
CY2024Q1	us-gaap	Assets Assets	13358716	usd
CY2023Q2	us-gaap	Assets Assets	14106340	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1183285	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1608735	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	345545	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	375713	usd
CY2023Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	16171	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1528830	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2000619	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	725236	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	15994	usd
CY2024Q1	us-gaap	Liabilities Liabilities	2254066	usd
CY2023Q2	us-gaap	Liabilities Liabilities	2016613	usd
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6344970	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6344970	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3328191	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3328191	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	80606863	usd
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	77620252	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	37507306	usd
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	35741115	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-107138088	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-101400209	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	128569	usd
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	128569	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	11104650	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	12089727	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13358716	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14106340	usd
CY2024Q1	us-gaap	Revenues Revenues	1172601	usd
CY2023Q1	us-gaap	Revenues Revenues	1033925	usd
	us-gaap	Revenues Revenues	3314663	usd
	us-gaap	Revenues Revenues	1824496	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	883143	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	841414	usd
	us-gaap	Cost Of Revenue CostOfRevenue	2416417	usd
	us-gaap	Cost Of Revenue CostOfRevenue	1415068	usd
	inm	Inventorys Writedown InventorysWritedown	263404	usd
	inm	Inventorys Writedown InventorysWritedown	576772	usd
CY2024Q1	us-gaap	Gross Profit GrossProfit	289458	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	192511	usd
	us-gaap	Gross Profit GrossProfit	634842	usd
	us-gaap	Gross Profit GrossProfit	-167344	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	656764	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	878303	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2558648	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3108312	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1374095	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1412727	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4036784	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4438083	usd
CY2024Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	54767	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	50689	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	164833	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	148786	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-48156	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-2733	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-36717	usd
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-79287	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	2133782	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	2344452	usd
	us-gaap	Operating Expenses OperatingExpenses	6796982	usd
	us-gaap	Operating Expenses OperatingExpenses	7774468	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	121458	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	155497	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	424261	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	343881	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1722866	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1996444	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5737879	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7597931	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-1500	usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-11300	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1722866	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1997944	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5737879	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7609231	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.18
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.6
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.82
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.53
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9612973	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	3328191	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6961938	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2156283	shares
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	12089727	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-2536828	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	25191	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	9578090	usd
CY2023Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	4654042	usd
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	-1478185	usd
CY2023Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	18264	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	12772211	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1722866	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	55305	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	11104650	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	9078541	usd
CY2022Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5322500	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	419	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3510200	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	116680	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	11007940	usd
CY2022Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5357507	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	53	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	-2101087	usd
CY2022Q4	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	70638	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14335051	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	174	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1997944	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	50357	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	12387638	usd
	us-gaap	Net Income Loss NetIncomeLoss	-5737879	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7609231	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	164833	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	148786	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	98760	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	237675	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	287824	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	296239	usd
	us-gaap	Interest Income Short Term Investment Other InterestIncomeShortTermInvestmentOther	1271	usd
	us-gaap	Interest Income Short Term Investment Other InterestIncomeShortTermInvestmentOther	392	usd
	us-gaap	Unrealized Loss On Foreign Currency Derivatives Before Tax UnrealizedLossOnForeignCurrencyDerivativesBeforeTax	2607	usd
	us-gaap	Unrealized Loss On Foreign Currency Derivatives Before Tax UnrealizedLossOnForeignCurrencyDerivativesBeforeTax	2138	usd
	us-gaap	Inventory Write Down InventoryWriteDown	263404	usd
	us-gaap	Inventory Write Down InventoryWriteDown	576772	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	25085	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-159000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-584151	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	520653	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-102022	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-4908	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-5507	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-52718	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	107357	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-425446	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-585341	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-16171	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	16171	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-289302	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-317490	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-5956668	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6625265	usd
	us-gaap	Payment For Contingent Consideration Liability Investing Activities PaymentForContingentConsiderationLiabilityInvestingActivities	500000	usd
	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	42513	usd
	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	42513	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9293	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	128198	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-9293	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-628198	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	4654042	usd
	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	10680654	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4654042	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10680654	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1311919	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3427191	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8912517	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6176866	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7600598	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	9604057	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	11300	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	3508749	usd
	us-gaap	Stock Issued1 StockIssued1	325699	usd
	us-gaap	Stock Issued1 StockIssued1	691483	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	968376	usd
	us-gaap	Nature Of Operations NatureOfOperations	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>1.</b></span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CORPORATE INFORMATION AND CONTINUING OPERATIONS</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Business</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 14.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">InMed Pharmaceuticals Inc. (“InMed” or the “Company”) was incorporated in the Province of British Columbia on May 19, 1981 under the <i>Business Corporations Act</i> of British Columbia. InMed is a clinical stage pharmaceutical company developing a pipeline of proprietary small molecule drug candidates, targeting the treatment of diseases with high unmet medical needs as well as developing proprietary manufacturing technologies to produce bulk rare cannabinoids for sale as ingredients in the health and wellness industry.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 14.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">The Company’s shares are listed on the Nasdaq Capital Market (“Nasdaq”) under the trading symbol “INM”. InMed’s office and principal place of business is located at #310 – 815 West Hastings Street, Vancouver, B.C., Canada, V6C 1B4.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 1.2pt"><b><i> </i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Going Concern</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: 14.7pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">In accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) 2014-15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern (Subtopic 205-40), the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify; text-indent: -21.3pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">Through March 31, 2024, the Company has funded its operations primarily with proceeds from the sale of common stock. The Company has incurred recurring losses and negative cash flows from operations since its inception, including net losses of approximately $5.7 million and $7.6 million for the nine months ended March, 2024 and 2023, respectively. In addition, the Company had an accumulated deficit of approximately $107.1 million as of March 31, 2024. The Company expects to continue to generate operating losses for the foreseeable future.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 21.3pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">As of the issuance date of these condensed consolidated financial statements, the Company expects its cash, cash equivalents and short-term investments of $7.6 million as of March 31, 2024, will be sufficient to fund its operating expenses and capital expenditure requirements into the fourth quarter of calendar 2024, depending on the level and timing of realizing BayMedica, LLC, a wholly-owned subsidiary of the Company (“BayMedica”), revenues from the sale of bulk rare cannabinoids as ingredients in the health and wellness sector as well as the level and timing of the Company’s operating expenses. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. The Company has concluded that there is substantial doubt about its ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0.25in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">The Company expects to continue to seek additional funding through equity financings, debt financings or other capital sources, including collaborations with other companies, government contracts or other strategic transactions. The Company may not be able to obtain financing on acceptable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s existing shareholders.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In connection with the Company’s assessment of going concern considerations in accordance with Subtopic 205-40, management has determined that the Company’s liquidity condition raises substantial doubt about the Company’s ability to continue as a going concern, which is considered to be for a period of one year from the issuance of these financial statements. These condensed consolidated financial statements do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts of classification of liabilities that might result from the outcome of this uncertainty. Such adjustments could be material. </span></p>
	us-gaap	Net Income Loss NetIncomeLoss	-5700000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7600000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-107100000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	7600000	usd
	us-gaap	Revenue Recognition Allowances RevenueRecognitionAllowances	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Reclassifications</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">Certain prior year amounts in the condensed consolidated financial statements and the notes thereto have been reclassified where necessary to conform to the current year’s presentation. These reclassifications did not affect the prior period’s total assets, total liabilities, stockholders’ deficit, net loss or net cash used in operating activities. During the three months and nine months ended March 31, 2024, we adopted a change in presentation on our condensed consolidated statements of operations in order to include foreign exchange loss in operating expenses. The Company has adopted ASU 2023-07 - <i>Improvements to Reportable Segment Disclosures </i>which has required prior period to reflect the change in presentation. Refer to discussion on <i>Recent Accounting Pronouncements</i> below.</p>
	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Use of Estimates</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">The preparation of financial statements in compliance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amount of assets and liabilities as of the balance sheet date, and the corresponding revenues and expenses for the periods reported. It also requires management to exercise judgment in applying the Company’s accounting policies. In the future, actual experience may differ from these estimates and assumptions. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates are significant to these condensed consolidated financial statements are the application of the going concern assumption, and determining the fair value of share-based payments, income tax provisions, write-down of inventories to net realizable value, and warrant valuations.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><b><i> </i></b></p>
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1648747	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><b><i>Concentration of Credit Risk and Other Risks and Uncertainties</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">At times, the Company’s cash balances may exceed the Federal Deposit Insurance Corporation (“FDIC”) or Canadian Deposit Insurance Corporation (“CDIC”) insurable limits. To date, the Company has not experienced any losses related to these balances. The uninsured cash balance as of March 31, 2024 and June 30, 2023, was $3.0 million and $3.8 million respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify; text-indent: 13.5pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">The Company’s customers are primarily concentrated in the U.S.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">As of March 31, 2024, the Company had four customers with an accounts receivable balance representing 39%, 32%, 16%, and 10% of total accounts receivable, respectively. As of June 30, 2023, we had three customers with an accounts receivable balance representing 41%, 30% and 15% of total accounts receivable, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">For the three months ended March 31, 2024, the Company had four customers that accounted for 29%, 21%, 16% and 16% of revenue, respectively. For the three months ended March 31, 2023, the Company had four customers that accounted for 22%, 20%, 17% and 11% of revenue, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.25in">For the nine months ended March 31, 2024, the Company had four customers that accounted for 39%, 16%, 15% and 10% of revenue, respectively. For the nine months ended March 31, 2023, the Company had four customers that accounted for 17%, 15%, 14%, and 10% of revenue, respectively. This change is reflective of the Company’s transition to operating primarily through a distributor model in the year ended June 30, 2023.</p>
CY2024Q1	us-gaap	Cash Uninsured Amount CashUninsuredAmount	3000000	usd
CY2023Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	3800000	usd
	us-gaap	Pro Forma Weighted Average Shares Outstanding Diluted ProFormaWeightedAverageSharesOutstandingDiluted	255954	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	13882568	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3555456	shares
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1234341	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	925321	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1370969	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	723426	usd
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	196500	usd
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	208737	usd
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	439086	usd
CY2023Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	514113	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	558366	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	893506	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	1193952	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	1616356	usd
CY2024Q1	us-gaap	Weighted Average Cost Inventory Amount WeightedAverageCostInventoryAmount	357224	usd
CY2023Q2	us-gaap	Weighted Average Cost Inventory Amount WeightedAverageCostInventoryAmount	93820	usd
	us-gaap	Inventory Write Down InventoryWriteDown	263404	usd
	us-gaap	Inventory Write Down InventoryWriteDown	576772	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2605310	usd
CY2024Q1	us-gaap	Depreciation Depreciation	14220	usd
CY2023Q1	us-gaap	Depreciation Depreciation	10586	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	95615	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	91935	usd
	us-gaap	Depreciation Depreciation	42302	usd
	us-gaap	Depreciation Depreciation	26697	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	287824	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	296239	usd
CY2024Q1	inm	Finite Lived Intellectual Property FiniteLivedIntellectualProperty	1736420	usd
CY2023Q2	inm	Finite Lived Intellectual Property FiniteLivedIntellectualProperty	1736420	usd
CY2024Q1	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1191000	usd
CY2023Q2	us-gaap	Finite Lived Patents Gross FiniteLivedPatentsGross	1191000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2927420	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2927420	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1103675	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	981141	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1823745	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1946279	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P18Y
CY2024Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P18Y
	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P12Y
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	40993	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	40103	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	122531	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	122089	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	158935	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	158935	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	158935	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	158935	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	158935	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1029070	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1823745	usd
CY2024Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	402638	usd
CY2023Q2	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	544179	usd
CY2024Q1	inm	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	353465	usd
CY2023Q2	inm	Accrued Research And Development Expenses AccruedResearchAndDevelopmentExpenses	164587	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	54629	usd
CY2024Q1	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	205030	usd
CY2023Q2	us-gaap	Workers Compensation Liability Current WorkersCompensationLiabilityCurrent	542305	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	167523	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	357664	usd
CY2024Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1183285	usd
CY2023Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1608735	usd
CY2023Q4	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1248376	usd
CY2023Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	3012049	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.83
CY2023Q4	inm	Preferred Investment Of Fair Value Options PreferredInvestmentOfFairValueOptions	1251449	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1757032	usd
CY2024Q1	us-gaap	Common Stock Shares Subscriptions CommonStockSharesSubscriptions	1491138	usd
	inm	Fair Value Of Issuance Date FairValueOfIssuanceDate	1225230	usd
	inm	Investors Shares InvestorsShares	1540598	shares
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3500000	usd
CY2023Q4	us-gaap	Payments For Fees PaymentsForFees	560000	usd
CY2023Q4	inm	Warrants Shares Issued WarrantsSharesIssued	408511	shares
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y6M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P1Y4M24D
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1096085	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P4Y
CY2017Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.20	pure
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	700000	shares
CY2024Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	174353	shares
CY2023Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	51633	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum	0.20	pure
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	0.37
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	102642	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	31.28
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	580400	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.37
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	4567	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	386.97
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	678475	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.96
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	112920	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	15.39
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	565555	shares
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	0.47
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	55305	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	50357	usd
CY2024Q1	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	9768	usd
CY2023Q1	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	28442	usd
CY2024Q1	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	6659	usd
CY2023Q1	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	21915	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	98760	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	237675	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	57231	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	137555	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	41024	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	100120	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	146413	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	388703	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	364043	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	374965	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	31325	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1159035	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	88254	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	1070781	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	345545	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	725236	usd
	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	1095104	usd
	us-gaap	Subordinated Borrowing Interest Rate SubordinatedBorrowingInterestRate	0.0615	pure
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	968376	usd
	us-gaap	Cost Direct Material CostDirectMaterial	1500000	usd
	us-gaap	Equipment Expense EquipmentExpense	1000000	usd
CY2024Q1	us-gaap	Borrowings Under Guaranteed Investment Agreements BorrowingsUnderGuaranteedInvestmentAgreements	43085	usd
CY2023Q2	us-gaap	Borrowings Under Guaranteed Investment Agreements BorrowingsUnderGuaranteedInvestmentAgreements	44422	usd
CY2021Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	700	shares
CY2021Q1	inm	Common Shares Purchased CommonSharesPurchased	700	shares
CY2023Q2	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	300000	usd
CY2024Q1	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q1	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q1	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q1	inm	Inventorys Writedown InventorysWritedown		usd
CY2023Q1	inm	Inventorys Writedown InventorysWritedown		usd
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet		usd
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9612973	shares
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent		usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour		usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001728328

Files In Submission

Name	View Source	Status
inm-20240331_cal.xml	Edgar Link	unprocessable
0001213900-24-042467-index-headers.html	Edgar Link	pending
0001213900-24-042467-index.html	Edgar Link	pending
0001213900-24-042467.txt	Edgar Link	pending
0001213900-24-042467-xbrl.zip	Edgar Link	pending
ea0204878-10q_inmedpharma.htm	Edgar Link	pending
ea020487801ex10-1_inmed.htm	Edgar Link	pending
ea020487801ex31-1_inmed.htm	Edgar Link	pending
ea020487801ex31-2_inmed.htm	Edgar Link	pending
ea020487801ex32-1_inmed.htm	Edgar Link	pending
ea020487801ex32-2_inmed.htm	Edgar Link	pending
ex10-1_001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
inm-20240331.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
inm-20240331_def.xml	Edgar Link	unprocessable
inm-20240331_lab.xml	Edgar Link	unprocessable
inm-20240331_pre.xml	Edgar Link	unprocessable
ea0204878-10q_inmedpharma_htm.xml	Edgar Link	completed
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INM
InMed Pharmaceuticals Inc. Stock $inm

2024 Q2 Form 10-Q Financial Statement

#000121390024042467 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INM InMed Pharmaceuticals Inc. Stock $inm

2024 Q2 Form 10-Q Financial Statement

#000121390024042467 Filed on May 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INM
InMed Pharmaceuticals Inc. Stock $inm